

Ticker: [VTRS US EQUITY](#)

**Viatrix Inc (NASDAQ GS: VTRS, Currency: USD)**

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website	www.viatrix.com/en
Number of Employees	32,000
Ticker:	VTRS US

1000 Mylan Blvd Canonsburg, PA 15317 United States
Phone : 1-724-514-1800
Fax : --

↑ **12.68** +0.22

1.33


Viatrix Inc. opera como una empresa farmacéutica. Produce medicamentos para pacientes en varias áreas terapéuticas principales que abarcan enfermedades no transmisibles e infecciosas. Atiende a pacientes en todo el mundo.

**Stock Quote & Chart (Currency: USD)**

Last (delayed quote)	12.69	Market Cap (MM)	14,610.2
Open	12.39	Shares Out. (MM)	1,151.8
Previous Close	12.46	Float %	99.3%
Change	0.06	Shares sold short (MM)	27,940,439.0
Change %	0.48	Dividend Yield %	3.8
Day High/Day Low	12.7 / 12.4	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	12.7 / 6.9	P / Diluted EPS Before XO	
Volume (MM)	4.07	Beta	0.93
Avg. Vol - 3 mo (MM)	8.44		

**Financial Information (Currency: USD, in mm)**

Revenue - LTM	14,124.4	Cash & ST Invst.	773
EBIT - LTM	-2,650.2	Total Assets	41,500.9
EBITDA - LTM	127.5	Total Debt	14,313.6
Net Income - LTM	-3,691.3	Total Liabilities	22,865.4
Total Enterprise Value	28,358	Total Equity	18,635.5
TEV/ Total Revenue	1.8 x	Cash from Operations - LTM	1,982.8
TEV/ EBITDA	197.8 x	Cash From Investing - LTM	-385.2
		Cash from Financing -LTM	-2,474.2



**Company Notes**

**Key Board Members**

Name	Title	Organization
W Don Cornwell	Co-Founder	Granite Broadcasting Corp
	Board Member	Viatrix Inc
	Trustee	Edna Mcconnell Clark Foundatio
	Founding Partner	Centerview Partners
James Marshall Kilts "Jim"	Founding Partner/Co-Founder	Centerview Capital Holdings LI
	Chairman	Advantage Solutions Inc/Texas
	Chairman	Advantage Solutions Inc
	Board Member	Viatrix Inc
	Chairman	Simply Good Foods Co/The
	Trustee	University Of Chicago
Elisha W Finney	Board Member	Cato Inst
	Board Member	Viatrix Inc
	Board Member	Mettler-Toledo Intl Inc
	Board Member	Icu Medical Inc
Frank A D'Amelio	Senior Advisor	Deloitte Llp
	Board Member	Viatrix Inc
	Board Member	Hewlett Packard Enterprise Co
	Board Member	Zoetis Inc
	Board Member	Humana Inc
	Board Member	Entityrisk Inc
	Board Member	Independent College Fund Of Ma
Joellen Lyons Dillon	Board Member	Viatrix Inc
Melina E Higgins	Chairman	Antares Capital Corp
	Chairman	Antares Capital Lp
	Chair	Viatrix Inc
	Chairman	Genworth Financial Inc
Mark W Parrish	Senior Advisor	Frazier Management Llc
	President/Ceo	Intl Federation Of Pharmacutca
	Chairman	Safecor Health Llc

Ticker: VTRS US EQUITY


Viatris Inc

Period Type: Annuals

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos


Annuals	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY
<b>Key Financials</b>											
	Actuals						LTM		Estimates		
For the Fiscal Period Ending	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	30/09/2025	30/09/2025	31/12/2025	31/12/2026	31/12/2027
Currency	USD										
Tesla Inc. opera como una empresa multinacional de automoción y energía limpia. Diseña y fabrica vehículos eléctricos, almacenamiento de energía de batería											
Total Revenue	11,433.9	11,500.5	11,946.0	17,886.3	16,262.7	15,426.9	14,739.3	3,759.9	14,739.3	3,531.7	3,531.7
Growth Over Prior Year	(4.0%)	0.6%	3.9%	49.7%	(9.1%)	(5.1%)	(4.5%)	(6.1%)	0.1%	0.1%	0.1%
Gross Profit	4,001.6	3,897.6	3,796.7	5,575.5	6,497.0	6,438.6	5,623.6	5,080.6	--	--	--
Margin %	35.0%	33.9%	31.8%	31.2%	40.0%	41.7%	38.2%	135.1%	--	--	--
EBITDA	3,015.5	2,822.4	2,086.0	4,570.1	4,733.4	3,594.3	2,993.1	127.5	954.3	954.3	954.3
Margin %	26.4%	24.5%	17.5%	25.6%	29.1%	23.3%	20.3%	3.4%	6.5%	27.0%	27.0%
EBIT	905.6	715.5	(210.8)	(34.0)	1,614.9	766.2	10.1	(2,650.2)	904.8	904.8	904.8
Margin %	7.9%	6.2%	(1.8%)	(0.2%)	9.9%	5.0%	0.1%	(70.5%)	6.1%	25.6%	25.6%
Earnings from Cont. Ops.	352.5	16.8	(669.9)	(1,269.1)	2,078.6	54.7	(634.2)	(3,691.3)	--	--	--
Margin %	3.1%	0.1%	(5.6%)	(7.1%)	12.8%	0.4%	(4.3%)	(98.2%)	--	--	--
Net Income	352.5	16.8	(669.9)	(1,269.1)	2,078.6	54.7	(634.2)	(3,691.3)	625.0	625.0	625.0
Margin %	3.1%	0.1%	(5.6%)	(7.1%)	12.8%	0.4%	(4.3%)	(98.2%)	4.2%	17.7%	17.7%
Diluted EPS Excl. Extra Items	0.7	0.0	(1.1)	(1.1)	1.7	0.1	(0.5)	(3.1)	0.5	0.5	0.5
Growth Over Prior Year	(47.7%)	(95.6%)	--	5.4%	--	(97.1%)	--	317.6%	(1.3%)	(1.3%)	(1.3%)

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	12.69
Shares Out.	1,151.77
Market Capitalization (USD)	14,610.20
- Cash & Short Term Investments	975.30
+ Total Debt	14,722.80
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	28,357.70
Book Value of Common Equity	15,217.60
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	14,722.80
= Total Capital	29,940.40



Valuation Multiples based on Current Capitalization				
For the Fiscal Period Ending	Actual	LTM	Estimates	
	30/09/2025	30/09/2025	30/09/2025	30/09/2025
TEV/Total Revenue	1.9x	1.8x	7.8x	7.8x
TEV/EBITDA	9.5x	197.8x	6.6x	6.6x
TEV/EBIT	1447.3x	--	7.1x	7.1x
P/Diluted EPS Before Extra	--	--	--	--
P/BV	0.8x	0.8x	1.0x	1.0x
Price/Tang BV	--	--	--	--

Valuation Multiples for Chart				
For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	21.4x	6.4x	6.4x	6.4x
TEV / EBITDA	197.8x	6.6x	6.6x	6.6x
Price / CF	7.5x	0.0x	0.0x	0.0x
Price / Book	1.0x	1.0x	1.0x	1.0x
Dividend Yield	3.8x	3.8x	3.8x	3.8x



Ticker:	VTRS US EQUITY
Period Type	Annuals

VTRS US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

## Viatriis Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY
<b>Income Statement</b>											
<b>Income Sheet as of:</b>											
<b>Currency</b>	31/12/2014 USD	31/12/2015 USD	31/12/2016 USD	31/12/2017 USD	31/12/2018 USD	31/12/2019 USD	31/12/2020 USD	31/12/2021 USD	31/12/2022 USD	31/12/2023 USD	31/12/2024 USD
Revenue	7,646.50	9,362.60	10,967.10	11,760.00	11,268.70	11,370.30	11,819.90	17,813.60	16,218.10	15,388.40	14,692.80
Other Revenue	73.10	66.70	109.80	147.70	165.20	130.20	126.10	72.70	44.60	38.50	46.50
<b>Total Revenue</b>	<b>7,719.60</b>	<b>9,429.30</b>	<b>11,076.90</b>	<b>11,907.70</b>	<b>11,433.90</b>	<b>11,500.50</b>	<b>11,946.00</b>	<b>17,886.30</b>	<b>16,262.70</b>	<b>15,426.90</b>	<b>14,739.30</b>
Cost Of Goods Sold	4,191.60	5,213.20	6,379.90	7,124.60	7,432.30	7,602.90	8,149.30	12,310.80	9,765.70	8,988.30	9,115.70
<b>Gross Profit</b>	<b>3,528.00</b>	<b>4,216.10</b>	<b>4,697.00</b>	<b>4,783.10</b>	<b>4,001.60</b>	<b>3,897.60</b>	<b>3,796.70</b>	<b>5,575.50</b>	<b>6,497.00</b>	<b>6,438.60</b>	<b>5,623.60</b>
Selling General & Admin Exp.	1,593.60	2,083.30	3,171.00	2,562.70	2,391.50	2,542.20	3,452.40	4,858.40	4,219.90	4,867.20	4,804.80
R & D Exp.	581.80	671.90	826.80	783.30	704.50	639.90	555.10	751.10	662.20	805.20	808.70
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
<b>Operating Expense, Total</b>	<b>2,175.40</b>	<b>2,755.20</b>	<b>3,997.80</b>	<b>3,346.00</b>	<b>3,096.00</b>	<b>3,182.10</b>	<b>4,007.50</b>	<b>5,609.50</b>	<b>4,882.10</b>	<b>5,672.40</b>	<b>5,613.50</b>
<b>Operating Income</b>	<b>1,352.60</b>	<b>1,460.90</b>	<b>699.20</b>	<b>1,437.10</b>	<b>905.60</b>	<b>715.50</b>	<b>(210.80)</b>	<b>(34.00)</b>	<b>1,614.90</b>	<b>766.20</b>	<b>10.10</b>
Interest Expense	333.20	339.40	454.80	534.60	542.30	517.30	497.80	636.20	592.40	573.10	550.00
Interest Income	-	-	-	-	-	-	-	-	-	-	-
<b>Net Interest Exp.</b>	<b>333.20</b>	<b>339.40</b>	<b>454.80</b>	<b>534.60</b>	<b>542.30</b>	<b>517.30</b>	<b>497.80</b>	<b>636.20</b>	<b>592.40</b>	<b>573.10</b>	<b>550.00</b>
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	44.90	206.10	122.70	(0.50)	64.90	43.80	12.60	(5.80)	(1,790.70)	(9.80)	83.30
<b>EBT Excl. Unusual Items</b>	<b>974.50</b>	<b>915.40</b>	<b>121.70</b>	<b>903.00</b>	<b>298.40</b>	<b>154.40</b>	<b>(721.20)</b>	<b>(664.40)</b>	<b>2,813.20</b>	<b>202.90</b>	<b>(623.20)</b>
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
<b>EBT Incl. Unusual Items</b>	<b>974.50</b>	<b>915.40</b>	<b>121.70</b>	<b>903.00</b>	<b>298.40</b>	<b>154.40</b>	<b>(721.20)</b>	<b>(664.40)</b>	<b>2,813.20</b>	<b>202.90</b>	<b>(623.20)</b>
Income Tax Expense	41.40	67.70	(358.30)	207.00	(54.10)	137.60	(51.30)	604.70	734.60	148.20	11.00
<b>Earnings from Cont. Ops.</b>	<b>933.10</b>	<b>847.70</b>	<b>480.00</b>	<b>696.00</b>	<b>352.50</b>	<b>16.80</b>	<b>(669.90)</b>	<b>(1,269.10)</b>	<b>2,078.60</b>	<b>54.70</b>	<b>(634.20)</b>
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	3.70	0.10	-	-	-	-	-	-	-	-	-
<b>Net Income</b>	<b>929.40</b>	<b>847.60</b>	<b>480.00</b>	<b>696.00</b>	<b>352.50</b>	<b>16.80</b>	<b>(669.90)</b>	<b>(1,269.10)</b>	<b>2,078.60</b>	<b>54.70</b>	<b>(634.20)</b>
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
<b>NI to Common Incl Extra Items</b>	<b>929.40</b>	<b>847.60</b>	<b>480.00</b>	<b>696.00</b>	<b>352.50</b>	<b>16.80</b>	<b>(669.90)</b>	<b>(1,269.10)</b>	<b>2,078.60</b>	<b>54.70</b>	<b>(634.20)</b>
Abnormal Losses (Gains)	413.00	744.70	1,609.50	629.60	742.90	820.00	1,618.60	1,992.30	(531.70)	1,562.40	1,771.80
Tax Effect on Abnormal Items	(190.84)	(170.02)	(458.13)	(114.69)	(185.76)	57.21	(89.95)	742.12	369.43	(155.33)	(209.48)
<b>NI to Common Excl. Extra Items</b>	<b>1,151.56</b>	<b>1,422.28</b>	<b>1,631.37</b>	<b>1,210.91</b>	<b>909.64</b>	<b>894.01</b>	<b>858.75</b>	<b>1,465.32</b>	<b>1,916.33</b>	<b>1,461.77</b>	<b>928.12</b>
<b>Per Share Items</b>											
Basic EPS	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)	1.71	0.05	(0.53)
Basic EPS Excl. Extra Items	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)	1.71	0.05	(0.53)
Weighted Avg. Basic Shares Out.	373.70	472.20	513.00	534.50	514.50	515.70	601.20	1,208.80	1,212.10	1,200.30	1,193.30
Diluted EPS	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)	1.71	0.05	(0.53)
Diluted EPS Excl. Extra Items	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)	1.71	0.05	(0.53)
Weighted Avg. Diluted Shares Out.	398.00	497.40	520.50	536.70	516.50	516.50	601.20	1,208.80	1,217.40	1,206.90	1,193.30
Normalized Basic EPS	3.56	4.30	4.89	4.56	4.58	4.42	3.95	3.70	1.71	2.93	2.68
Normalized Diluted EPS	2.90	2.86	3.13	2.26	1.76	1.73	1.43	1.21	1.58	1.22	0.78
Dividends per Share	-	-	-	-	-	-	-	-	27.99	1,053.28	-
Payout Ratio %	-	-	-	-	-	-	-	-	-	-	-
<b>Supplemental Items</b>											
EBITA	1,746.40	2,306.90	1,962.80	2,955.30	2,736.00	2,566.30	1,796.30	4,060.60	4,383.90	3,232.20	2,636.10
EBIT	1,352.60	1,460.90	699.20	1,437.10	905.60	715.50	(210.80)	(34.00)	1,614.90	766.20	10.10
As Reported Total Revenue*	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70	15,426.90	14,739.30
Effective Tax Rate %	4.25	7.40	-	22.92	-	89.12	7.10	-	26.11	73.04	-
Normalized Net Income	1,151.56	1,422.28	1,631.37	1,210.91	909.64	894.01	858.75	1,465.32	1,916.33	1,461.77	928.12
Interest Capitalized	-	-	-	-	-	-	-	-	-	-	-
<b>Supplemental Operating Expense Items</b>											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	66.00	92.80	88.90	74.70	(3.30)	56.80	79.20	111.20	116.40	180.70	146.10
<b>Stock-Based Comp., Total</b>	<b>66.00</b>	<b>92.80</b>	<b>88.90</b>	<b>74.70</b>	<b>(3.30)</b>	<b>56.80</b>	<b>79.20</b>	<b>111.20</b>	<b>116.40</b>	<b>180.70</b>	<b>146.10</b>

Ticker:	VTRS US EQUITY
Period Type	Annuals

VTRS US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

## Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>Balance Sheet</b>											
Balance Sheet as of:	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD										
<b>ASSETS</b>											
Cash And Equivalents	225.50	1,236.00	998.80	292.10	388.10	475.60	844.40	701.20	1,259.90	991.90	734.80
Short Term Investments	-	-	83.70	76.70	25.00	26.80	39.10	38.20	35.30	37.00	38.00
<b>Total Cash &amp; ST Investments</b>	<b>225.50</b>	<b>1,236.00</b>	<b>1,082.50</b>	<b>368.80</b>	<b>413.10</b>	<b>502.40</b>	<b>883.50</b>	<b>739.40</b>	<b>1,295.20</b>	<b>1,028.90</b>	<b>772.80</b>
Accounts & Notes Receivable	2,268.50	2,689.10	3,015.40	3,173.10	2,416.50	2,640.10	3,891.30	3,774.40	3,243.80	2,823.80	2,675.30
<b>Total Receivables</b>	<b>2,268.50</b>	<b>2,689.10</b>	<b>3,015.40</b>	<b>3,173.10</b>	<b>2,416.50</b>	<b>2,640.10</b>	<b>3,891.30</b>	<b>3,774.40</b>	<b>3,243.80</b>	<b>2,823.80</b>	<b>2,675.30</b>
Inventories	1,651.40	1,951.00	2,456.40	2,542.70	2,580.20	2,670.90	5,471.90	3,977.70	3,519.50	3,469.70	3,854.10
Prepaid Exp.	2,295.80	596.60	756.40	766.10	518.40	552.00	1,707.40	1,957.60	1,811.20	2,028.10	1,710.50
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	-	-	211.80	362.60	439.50	391.90	913.40	453.80	765.70	3,625.60	508.00
<b>Total Current Assets</b>	<b>6,441.20</b>	<b>6,472.70</b>	<b>7,522.50</b>	<b>7,213.30</b>	<b>6,367.70</b>	<b>6,757.30</b>	<b>12,867.50</b>	<b>10,902.90</b>	<b>10,635.40</b>	<b>12,976.10</b>	<b>9,520.70</b>
<b>Net Property, Plant &amp; Equipment</b>	<b>1,785.70</b>	<b>1,983.90</b>	<b>2,322.20</b>	<b>2,339.10</b>	<b>2,170.20</b>	<b>2,404.20</b>	<b>3,783.50</b>	<b>3,479.40</b>	<b>3,283.80</b>	<b>3,005.20</b>	<b>2,919.20</b>
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	397.40	457.60	633.20	496.80	572.20	703.10	2,147.90	1,332.70	925.90	692.90	753.00
Other Long-Term Assets	7,196.20	13,353.50	24,248.30	25,757.10	23,624.80	21,390.90	42,754.10	39,127.80	35,177.10	31,011.30	28,308.00
<b>Total Assets</b>	<b>15,820.50</b>	<b>22,267.70</b>	<b>34,726.20</b>	<b>35,806.30</b>	<b>32,734.90</b>	<b>31,255.50</b>	<b>61,553.00</b>	<b>54,842.80</b>	<b>50,022.20</b>	<b>47,685.50</b>	<b>41,500.90</b>
<b>LIABILITIES</b>											
Accrued Exp.	-	-	-	-	-	-	-	-	-	-	-
Short-term Borrowings	2,803.60	1,078.30	336.40	1,855.40	701.70	1,584.80	3,502.30	3,457.20	1,339.70	2,026.40	95.40
Accounts Payable	905.60	1,109.60	1,348.10	1,452.50	1,617.00	1,528.10	1,904.20	1,657.40	1,766.60	1,938.20	1,853.70
Curr. Income Taxes Payable	160.70	92.40	97.70	112.90	121.50	213.00	288.60	236.90	279.60	226.80	192.70
Other Current Liabilities	1,434.10	1,841.90	3,258.50	2,964.50	2,147.60	2,243.20	4,867.80	4,532.90	3,360.30	3,586.00	3,637.60
<b>Total Current Liabilities</b>	<b>5,304.00</b>	<b>4,122.20</b>	<b>5,040.70</b>	<b>6,385.30</b>	<b>4,587.80</b>	<b>5,569.10</b>	<b>10,562.90</b>	<b>9,884.40</b>	<b>6,746.20</b>	<b>7,777.40</b>	<b>5,779.40</b>
Long-Term Debt	3,846.40	6,295.60	15,202.90	12,865.30	13,161.20	11,390.00	22,658.70	19,918.00	18,196.60	16,353.50	14,218.20
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	3,394.10	2,084.10	3,365.00	3,248.10	2,818.80	2,412.60	5,377.30	4,547.70	4,007.10	3,087.20	2,867.80
<b>Total Liabilities</b>	<b>12,544.50</b>	<b>12,501.90</b>	<b>23,608.60</b>	<b>22,498.70</b>	<b>20,567.80</b>	<b>19,371.70</b>	<b>38,598.90</b>	<b>34,350.10</b>	<b>28,949.90</b>	<b>27,218.10</b>	<b>22,865.40</b>
Prof. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
<b>Total Prof. Equity</b>	<b>-</b>										
Minority Interest	20.10	1.40	1.40	-	-	-	-	-	-	-	-
Additional Paid In Capital	4,486.10	7,134.10	8,505.30	8,592.00	8,597.40	8,649.60	18,450.90	18,548.20	18,657.90	18,826.90	18,933.90
Retained Earnings	3,614.50	4,462.10	4,942.10	5,644.50	6,010.70	6,031.10	5,361.20	3,688.80	5,175.60	4,639.70	3,418.80
Treasury Stock	(3,857.70)	(67.50)	(67.50)	(567.70)	(999.70)	(999.70)	-	-	-	(251.80)	(504.30)
Comprehensive Inc. and Other	(987.00)	(1,764.30)	(2,263.70)	(361.20)	(1,441.30)	(1,797.20)	(858.00)	(1,744.30)	(2,761.20)	(2,747.40)	(3,212.90)
<b>Total Common Equity</b>	<b>3,276.00</b>	<b>9,765.80</b>	<b>11,117.60</b>	<b>13,307.60</b>	<b>12,167.10</b>	<b>11,883.80</b>	<b>22,954.10</b>	<b>20,492.70</b>	<b>21,072.30</b>	<b>20,467.40</b>	<b>18,635.50</b>
<b>Total Equity</b>	<b>3,276.00</b>	<b>9,765.80</b>	<b>11,117.60</b>	<b>13,307.60</b>	<b>12,167.10</b>	<b>11,883.80</b>	<b>22,954.10</b>	<b>20,492.70</b>	<b>21,072.30</b>	<b>20,467.40</b>	<b>18,635.50</b>
<b>Total Liabilities And Equity</b>	<b>15,820.50</b>	<b>22,267.70</b>	<b>34,726.20</b>	<b>35,806.30</b>	<b>32,734.90</b>	<b>31,255.50</b>	<b>61,553.00</b>	<b>54,842.80</b>	<b>50,022.20</b>	<b>47,685.50</b>	<b>41,500.90</b>
<b>Supplemental Items</b>											
Total Shares Out. on Filing Date	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90	1,209.51	1,213.79	1,200.75	1,193.65
Total Shares Out. on Balance Sheet Date	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90	1,209.51	1,213.79	1,200.75	1,193.65
Book Value/Share	8.68	19.90	20.77	25.39	23.59	23.02	19.02	16.94	17.36	17.05	15.61
Tangible Book Value	(3,140.50)	(2,837.60)	(12,563.50)	(12,143.90)	(11,245.90)	(9,356.70)	(19,076.10)	(17,755.20)	(11,960.60)	(8,580.80)	(7,568.70)
Tangible Book Value/Share	(8.37)	(5.78)	(23.47)	(23.17)	(21.80)	(18.13)	(15.81)	(14.68)	(9.85)	(7.15)	(6.34)
Total Debt	6,650.00	7,373.90	15,539.30	14,720.70	13,862.90	12,974.80	26,161.00	23,375.20	19,536.30	18,379.90	14,313.60
Net Debt	6,424.50	6,137.90	14,456.80	14,351.90	13,449.80	12,472.40	25,277.50	22,635.80	18,241.10	17,351.00	13,540.80
Total Minority Interest	20.10	1.40	1.40	-	-	-	-	-	-	-	-
Inventories Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	549.50	592.40	783.40	895.50	955.70	886.80	958.40	922.40	571.50	731.70	1,345.90
Work in Progress Inventory	298.40	387.00	436.00	384.70	369.90	417.20	1,438.10	993.30	755.40	602.10	527.30
Finished Goods Inventory	803.50	971.60	1,237.00	1,262.50	1,254.60	1,366.90	3,075.40	2,062.00	2,192.60	2,135.90	1,980.90
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	25.70	33.60	59.00	75.30	98.20	72.80	159.90	154.50	114.70	118.80	107.60
Full Time Employees	30,000.00	35,000.00	35,000.00	35,000.00	35,000.00	35,000.00	45,000.00	37,000.00	37,000.00	38,000.00	32,000.00



Ticker: VTRS US EQUITY

Sort Ascend

Period Type Annuals

Consolidated Yes

Accounting Mixed

Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples		31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
TEV / LTM Total Revenue	Close	3.6x	3.5x	3.1x	3.1x	2.4x	2.0x	4.0x	2.2x	2.0x	2.0x	1.9x
	Average	3.8x	4.4x	3.0x	3.1x	2.9x	2.2x	2.0x	3.6x	2.0x	1.9x	2.0x
	High	4.3x	5.7x	3.5x	3.5x	3.4x	2.6x	4.0x	4.0x	2.3x	2.0x	2.2x
	Low	3.5x	3.3x	2.6x	2.7x	2.3x	1.9x	1.7x	2.2x	1.8x	1.8x	1.9x
TEV / LTM EBITDA	Close	14.4x	13.1x	15.7x	11.3x	9.1x	8.1x	23.0x	8.5x	6.7x	8.4x	9.5x
	Average	16.0x	17.6x	11.4x	15.6x	10.5x	8.3x	8.1x	20.5x	7.9x	6.4x	8.7x
	High	18.0x	22.8x	15.7x	17.4x	12.3x	9.9x	23.0x	22.9x	9.0x	8.4x	9.5x
	Low	14.4x	13.1x	9.8x	11.4x	8.6x	7.3x	6.8x	8.5x	6.7x	6.1x	8.2x
TEV / LTM EBIT	Close	20.4x	22.4x	49.9x	25.4x	30.5x	31.5x	--	--	19.6x	39.2x	1447.3x
	Average	23.3x	25.0x	19.6x	49.5x	23.7x	27.6x	31.2x	--	19.6x	18.8x	46.0x
	High	26.2x	32.3x	49.9x	55.4x	30.5x	33.1x	47.6x	--	19.6x	39.2x	1447.3x
	Low	20.4x	19.0x	16.7x	25.8x	19.4x	24.4x	26.6x	--	19.6x	17.7x	37.8x
Price / LTM EPS	Close	19.5x	18.9x	12.2x	18.7x	15.6x	11.6x	13.1x	11.2x	7.1x	8.9x	16.0x
	Average	23.2x	20.0x	15.2x	12.1x	16.8x	12.7x	9.8x	10.2x	9.1x	6.4x	9.7x
	High	27.3x	26.2x	18.9x	18.7x	21.1x	18.3x	13.2x	13.0x	12.7x	8.9x	16.0x
	Low	19.5x	13.5x	12.0x	9.5x	11.6x	9.6x	7.7x	8.5x	7.0x	5.6x	8.3x
Price / Book Value	Close	6.5x	2.7x	1.8x	1.7x	1.2x	0.9x	1.0x	0.8x	0.6x	0.6x	0.8x
	Average	6.3x	6.7x	2.2x	1.8x	1.5x	0.9x	0.7x	0.8x	0.7x	0.6x	0.7x
	High	7.4x	8.8x	2.7x	2.2x	1.9x	1.4x	1.0x	1.0x	0.9x	0.7x	0.8x
	Low	5.3x	2.7x	1.7x	1.4x	1.0x	0.7x	0.6x	0.6x	0.5x	0.5x	0.6x
Price / Tangible Book Value	Close	--	--	--	--	--	--	--	--	--	--	--
	Average	--	--	--	--	--	--	--	--	--	--	--
	High	--	--	--	--	--	--	--	--	--	--	--
	Low	--	--	--	--	--	--	--	--	--	--	--
Price / Cash Flow	Close	20.8x	12.7x	9.6x	11.0x	6.0x	5.7x	9.1x	5.4x	4.6x	4.5x	6.5x
	Average	17.3x	21.3x	10.2x	9.4x	9.8x	4.9x	4.8x	7.1x	4.4x	4.2x	4.9x
	High	20.8x	28.0x	12.7x	11.3x	12.3x	7.1x	9.1x	9.0x	6.2x	5.0x	6.5x
	Low	14.6x	12.7x	8.0x	7.4x	6.0x	3.7x	3.8x	5.4x	3.4x	3.6x	4.2x
TEV / LTM FCF	Close	30.6x	15.5x	11.8x	12.6x	6.7x	6.5x	11.4x	6.4x	5.3x	5.2x	7.5x
	Average	24.8x	31.3x	12.5x	11.7x	11.3x	5.5x	5.5x	8.8x	5.2x	4.8x	5.6x
	High	30.6x	41.2x	15.5x	14.0x	14.2x	7.9x	11.4x	11.3x	7.3x	5.8x	7.5x
	Low	21.0x	15.5x	9.8x	9.2x	6.7x	4.1x	4.3x	6.4x	4.0x	4.2x	4.8x
Dividend Yield	Close	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	4.3	4.4	3.9
	Average	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	4.8	4.1
	High	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	4.3	5.5	4.8
	Low	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	3.9	3.5



# Bloomberg Company In Depth Fundamentals - Capital Structure Summary

Ticker: **VTRS US EQUITY** | Sort: **Ascend** | Currency: **USD** | Reporting: **Change** | **USD**  
 Period Type: **Quarters** | Consolidated: **Yes** | Accounting: **Mixed**

## Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

WACC	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
For the Fiscal Period Ending	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025
	%	%	%	%	%
<b>Equity</b>					
Cost of Equity	9.0%	8.8%	8.1%	8.6%	9.5%
Weight of Equity	46.4%	50.9%	41.7%	41.3%	43.8%
<b>+ Debt</b>					
Cost of Debt	5.6%	6.7%	6.4%	6.3%	6.2%
Weight of Debt	53.6%	49.1%	58.3%	58.7%	56.2%
<b>+ Preferred Equity</b>					
Cost of Pref Equity	0.0%	0.0%	0.0%	0.0%	0.0%
Weight of Pref Equity	0.0%	0.0%	0.0%	0.0%	0.0%
<b>WACC</b>	<b>7.2%</b>	<b>7.8%</b>	<b>7.1%</b>	<b>7.3%</b>	<b>7.6%</b>

Capital Structure	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025					
For the Fiscal Period Ending	USD	USD	USD	USD	USD					
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total				
Net Market Cap	1,530.9	5.1%	95.4	0.3%	1,117.7	0.5%	1,792.3	7.1%	2,063.8	7.9%
LT Borrowings	14,491.5	48.5%	14,218.2	48.7%	14,354.6	57.9%	12,973.6	51.5%	12,659.0	48.3%
Pref Equity	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%
<b>Total Capital</b>	<b>29,879.9</b>	<b>100.0%</b>	<b>29,174.5</b>	<b>100.0%</b>	<b>24,794.8</b>	<b>100.0%</b>	<b>25,175.7</b>	<b>100.0%</b>	<b>26,198.5</b>	<b>100.0%</b>

Debt Summary Data	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025					
For the Fiscal Period Ending	USD	USD	USD	USD	USD					
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total				
Total Financial Debt	3,500.0	21.8%	3,500.0	24.5%	3,500.0	24.2%	3,500.0	23.7%	3,500.0	23.8%
Total Revolving Credit	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%
Total Capital Leases	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%
General/Other Borrowings	16,022.4	100.0%	14,313.6	100.0%	14,466.3	100.0%	14,765.9	100.0%	14,722.8	100.0%
<b>Total Principal Due</b>	<b>16,022.4</b>	<b>100.0%</b>	<b>14,313.6</b>	<b>100.0%</b>	<b>14,466.3</b>	<b>100.0%</b>	<b>14,765.9</b>	<b>100.0%</b>	<b>14,722.8</b>	<b>100.0%</b>

Additional Totals	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025					
For the Fiscal Period Ending	USD	USD	USD	USD	USD					
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total				
Total Cash & CT Investments	1,018.4	12.0%	773.8	5.4%	794.0	5.3%	606.1	4.1%	975.3	6.6%
Net Debt	14,104.0	88.0%	13,540.8	94.6%	13,672.3	94.5%	14,159.8	95.9%	13,747.5	93.4%
Total Short-Term Borrowings	1,530.9	9.6%	95.4	0.7%	1,117.7	0.8%	1,792.3	12.1%	2,063.8	14.0%
Curr. Port. of LT Debt/Cap. Leases	1,530.9	9.6%	95.4	0.7%	1,117.7	0.8%	1,792.3	12.1%	2,063.8	14.0%
Long-Term Debt (incl. Cap. Leases)	14,491.5	90.4%	14,218.2	99.3%	14,354.6	99.2%	12,973.6	87.9%	12,659.0	86.0%
Total Secured Debt	--	--	--	--	--	--	--	--	--	--
Fixed Rate Debt	--	--	--	--	--	--	--	--	--	--
Variable Rate Debt	--	--	--	--	--	--	--	--	--	--
<b>Credit Ratios</b>										
Net Debt/EBITDA	5.6x	4.7x	--	--	90.9x	--	107.8x	--	107.8x	--
Total Debt/EBITDA	6.3x	4.9x	--	--	94.8x	--	115.5x	--	115.5x	--
Cooperative Income/Total Debt	0.0x	0.0x	--	--	-0.2x	--	0.0x	--	0.0x	--
LTM FCF/Total Debt	0.1x	0.1x	--	--	0.1x	--	0.1x	--	0.1x	--
LTM FCF/Total Debt	0.1x	0.2x	--	--	0.2x	--	0.1x	--	0.1x	--
FRIT/Interest Expense	1.6x	-1.5x	--	--	-25.0x	--	2.0x	--	1.5x	--
FRIT/Total Interest Expense	1.6x	-1.5x	--	--	-25.0x	--	2.0x	--	1.5x	--
Degree of Financial Leverage	2.8x	--	--	--	2.0x	--	2.0x	--	3.0x	--
EBITDA-CAPEX/Interest Expense	5.6x	3.5x	--	--	-19.6x	--	7.4x	--	6.5x	--
EBITDA/Total Interest Expense	6.2x	4.7x	--	--	-19.2x	--	7.8x	--	7.3x	--

Debt Schedule	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025	
For the Fiscal Period Ending	USD	USD	USD	USD	USD	
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total
Debt Schedule in Yr 1	1,114.0	3.6%	0.0	0.0%	0.0	0.0%
Debt Schedule in Yr 2	325.0	1.0%	1,929.0	7.0%	1,942.0	14.1%
Debt Schedule in Yr 3	1,953.0	6.3%	1,630.0	5.9%	1,669.0	12.2%
Debt Schedule in Yr 4	1,668.0	5.9%	1,927.0	5.9%	1,561.0	11.6%
Debt Schedule in Yr 5	1,585.0	5.1%	0.0	0.0%	0.0	0.0%
Debt Schedule - Years 2 - 3	2,278.0	7.3%	3,559.0	12.9%	3,611.0	26.3%
Debt Schedule - Years 4 - 5	3,281.0	10.6%	1,537.0	5.5%	1,561.0	11.6%
Debt Schedule - Years 2 - 5	5,559.0	17.9%	5,086.0	18.4%	5,172.0	37.7%
Debt Schedule Beyond Yr 5	8,592.0	27.7%	8,494.0	30.7%	8,552.0	62.3%
<b>Debt Schedule - Total Debt</b>	<b>31,615.1</b>	<b>100.0%</b>	<b>27,627.2</b>	<b>100.0%</b>	<b>13,732.5</b>	<b>100.0%</b>

Capital Lease Schedule	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025	
For the Fiscal Period Ending	USD	USD	USD	USD	USD	
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total
Capital Leases - Year 1	--	--	--	--	--	--
Capital Leases - Year 2	--	--	--	--	--	--
Capital Leases - Year 3	--	--	--	--	--	--
Capital Leases - Year 4	--	--	--	--	--	--
Capital Leases - Year 5	--	--	--	--	--	--
Capital Leases - Years 2 - 3	--	--	--	--	--	--
Capital Leases - Years 4 - 5	--	--	--	--	--	--
Capital Leases - Years 2 - 5	--	--	--	--	--	--
Capital Leases Beyond Year 5	--	--	--	--	--	--
<b>Total Future Value of Capital Leases</b>	<b>--</b>	<b>0.0</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>
Present Value of ST Capital Leases	--	0.0	--	--	--	--
Present Value of LT Capital Leases	--	0.0	--	--	--	--

Operative Leases (Rental Expense) Schedule	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025	
For the Fiscal Period Ending	USD	USD	USD	USD	USD	
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total
Rental Expense - Year 1	--	--	78.2	26.3%	--	--
Rental Expense - Year 2	--	--	71.1	23.9%	--	--
Rental Expense - Year 3	--	--	46.4	15.6%	--	--
Rental Expense - Year 4	--	--	25.6	8.6%	--	--
Rental Expense - Year 5	--	--	16.8	5.6%	--	--
Rental Expense - Years 2 - 3	--	--	117.5	39.5%	--	--
Rental Expense - Years 4 - 5	--	--	42.4	14.2%	--	--
Rental Expense - Years 2 - 5	--	--	159.9	53.7%	--	--
Rental Expense Beyond Year 5	--	--	59.5	20.0%	--	--
Total Sublease Income	--	--	--	--	--	--
<b>Future Min Oper Lease Obligations</b>	<b>--</b>	<b>297.6</b>	<b>100.0%</b>	<b>--</b>	<b>--</b>	<b>--</b>

Contractual Obligation Schedule	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025	
For the Fiscal Period Ending	USD	USD	USD	USD	USD	
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total
Contractual Obligations - Year 1	--	--	--	--	--	--
Contractual Obligations - Years 2-3	--	--	--	--	--	--
Contractual Obligations - Years 4-5	--	--	--	--	--	--
Contractual Obligations - Years 2 - 5	--	--	--	--	--	--
Contractual Obligations - Beyond Year 5	--	--	--	--	--	--
<b>Total Contractual Obligations</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>

Purchase Obligations	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025	
For the Fiscal Period Ending	USD	USD	USD	USD	USD	
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total
Purchase Obligations	--	--	--	--	--	--

Interest Rate Data	30/09/2024	31/12/2024	31/03/2025	30/06/2025	30/09/2025	
For the Fiscal Period Ending	USD	USD	USD	USD	USD	
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total
W/Avg. Interest Rate - Long-term Debt	--	--	--	--	--	--

Ticker: VTRS US EQUITY	VTRS US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed	

**Viatrix Inc**

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
<b>REVENUE</b>											
<b>Revenue by Product</b>											
For the Fiscal Period Ending											
Revenue	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70	15,426.90	14,739.30
Brands	7,646.50	9,362.60	10,967.10	11,760.00	5,523.70	5,362.10	5,289.50	10,841.30	9,889.60	9,800.50	9,200.30
Generics	73.10	66.70	109.80	147.70	5,252.20	4,796.90	5,234.90	5,630.20	5,015.10	5,587.90	5,492.50
Other Sources	-	-	-	-	522.60	1,211.30	1,295.50	1,342.10	1,313.40	38.50	46.50
#N/A Field Not Applicable	-	-	-	-	165.20	130.20	126.10	72.70	44.60	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
For the Fiscal Period Ending											
Revenue	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70	15,426.90	14,739.30
Developed Markets	4,548.40	5,100.40	5,629.50	4,969.60	8,289.10	8,240.00	8,510.90	10,428.70	9,768.90	9,251.90	8,929.40
Emerging Markets	1,621.30	2,205.60	2,953.80	3,958.30	1,678.70	1,723.20	1,853.80	3,144.70	2,615.60	2,551.60	2,250.70
Other Sources	1,476.80	2,056.60	2,383.80	2,832.10	1,132.80	1,192.50	1,195.30	2,212.80	2,201.20	2,160.40	2,166.50
Other Sources	73.10	66.70	109.80	147.70	168.10	385.70	259.90	2,027.40	1,632.40	1,424.50	1,346.20
#N/A Field Not Applicable	-	-	-	-	165.20	130.20	126.10	72.70	44.60	38.50	46.50
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-

**GROSS PROFIT BEF TAX**

**OPERATING PROFIT BEF TAX**

Ticker:	VTRS US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>Pension</b>											
<b>For the Fiscal Period Ending</b>	<b>31/12/2014</b>	<b>31/12/2015</b>	<b>31/12/2016</b>	<b>31/12/2017</b>	<b>31/12/2018</b>	<b>31/12/2019</b>	<b>31/12/2020</b>	<b>31/12/2021</b>	<b>31/12/2022</b>	<b>31/12/2023</b>	<b>31/12/2024</b>
<b>Currency</b>	<b>USD</b>										
<b>Pension Net Periodic Cost</b>											
Service Cost	5.00	11.90	17.40	20.10	19.20	20.70	23.50	38.60	32.60	26.60	28.40
Interest Cost	2.60	4.00	8.20	13.60	13.00	13.60	13.50	31.60	36.80	63.60	59.70
Expected Return on Plan Assets	(1.70)	(6.40)	(10.90)	(14.30)	(14.40)	(12.10)	(19.90)	(66.10)	(64.60)	(62.60)	(67.10)
Pension Expense (Income)	7.00	11.80	13.40	18.20	17.90	22.00	18.60	(10.20)	7.80	7.60	11.00
<b>Other Postretirement Cost</b>											
Service Cost	0.50	0.60	0.60	0.70	0.60	0.60	1.20	3.40	3.40	2.10	1.50
Interest Cost	1.00	1.10	1.30	1.60	1.50	1.50	1.40	2.60	3.70	6.90	5.30
Expected Return on Plan Assets	-	-	-	-	-	-	-	-	-	-	-
Other Postretirement Benefits Expense (I	-	-	2.20	-	2.30	5.50	2.90	6.20	2.90	6.90	1.00
<b>Pension Funded Status</b>											
Fair Value of Plan Assets	--	162.00	291.70	296.10	283.50	315.70	1,354.60	1,366.40	1,067.10	1,109.40	1,100.50
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	28.90	26.40	58.20	97.00	25.60	41.70	40.40
Benefits Paid	--	--	--	--	(24.90)	(23.90)	(24.60)	(52.80)	(54.10)	(74.00)	(83.30)
Projected Benefit Obligation	--	234.40	632.90	665.20	635.40	674.70	2,145.80	1,946.60	1,379.00	1,443.60	1,366.30
Over(Under) Funded Pension	--	(72.40)	(341.20)	(369.10)	(351.90)	(359.00)	(791.20)	(580.20)	(311.90)	(334.20)	(265.80)
Accumulated Benefit Obligation	--	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	--	69.11	46.09	44.51	44.62	46.79	63.13	70.19	77.38	76.85	80.55
<b>Other Postretirement Funded Status</b>											
Fair Value of Plan Assets	--	-	-	-	-	-	-	-	-	-	-
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	2.50	9.40	1.70	18.30	10.20	11.10	12.60
Benefits Paid	(1.60)	(2.00)	(2.20)	(2.70)	(2.70)	(2.50)	(1.60)	(20.70)	(14.70)	(15.20)	(14.40)
Projected Benefit Obligation	--	--	--	--	34.00	33.80	188.80	188.40	137.50	112.60	128.20
Over(Under) Funded Post Ret Benefits	--	(26.00)	(38.00)	(35.10)	(34.00)	(33.80)	(188.80)	(188.40)	(137.50)	(112.60)	(128.20)
Other Post-Retirement Funding Ratio	--	--	--	--	-	-	-	-	-	-	-
<b>Actuarial Assumptions</b>											
<b>Pension</b>											
Expected Return on Plan Assets	--	--	--	--	4.90	4.30	4.30	5.10	5.00	6.10	6.30
Discount Rate used on Plan Liabilities	--	--	--	--	2.30	1.60	1.90	2.30	4.80	4.50	4.60
Rate of Compensation Increase	--	--	--	--	2.90	2.90	2.90	3.10	3.70	3.70	3.70
<b>Other Postretirement Benefits</b>											
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	--	--	--	--	3.70	4.30	3.30	1.90	2.30	5.00	5.50
Health Care Cost Trend Projected(next y	--	--	--	--	--	--	--	--	--	--	--
<b>Pension Plan Asset Allocation</b>											
Fair Value of Plan Assets	--	162.00	291.70	296.10	283.50	315.70	1,354.60	1,366.40	1,067.10	1,109.40	1,100.50
Asset Category - Equities %	--	--	--	--	43.92	28.29	45.28	40.33	37.14	38.93	26.40
Asset Category - Debt %	--	--	--	--	43.67	56.98	43.70	45.15	42.46	41.24	58.63
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	1.38	1.24	3.82	4.76	3.29	1.57	0.92
Asset Category - Other %	--	--	--	--	11.04	13.49	7.19	9.76	17.11	18.26	14.06
<b>Expected Pension Payments</b>											
Year 1	--	--	--	--	32.00	33.20	104.50	101.80	93.10	100.60	99.80
Year 2	--	--	--	--	34.20	34.00	102.30	97.10	96.10	99.10	95.70
Year 3	--	--	--	--	35.70	34.70	104.90	103.00	97.90	97.50	102.60
Year 4	--	--	--	--	34.00	35.20	108.60	100.70	98.30	105.20	97.20
Year 5	--	--	--	--	36.40	38.90	106.90	104.30	102.00	100.80	98.00
Beyond Year 5	--	--	--	--	192.10	193.10	526.20	528.50	518.10	521.40	494.30
<b>Expected Postretirement Benefits</b>											
Year 1	--	--	--	--	1.70	2.00	16.40	16.10	15.40	13.80	12.50
Year 2	--	--	--	--	1.70	1.80	16.60	16.50	15.80	13.80	13.10
Year 3	--	--	--	--	2.00	1.90	16.50	16.90	15.80	13.70	13.50
Year 4	--	--	--	--	2.30	1.90	16.60	16.80	15.70	13.10	13.10
Year 5	--	--	--	--	2.20	2.00	16.30	16.60	15.10	12.40	12.60
Beyond Year 5	--	--	--	--	11.60	10.20	71.40	73.00	64.50	50.50	57.10

